Oncology
0 drugs are in development for Prostatic Neoplasms, Castration-Resistant.
- Companies
- 0
- Clinical trials
- 14
Prepared research question
Which programs lead the Prostatic Neoplasms, Castration-Resistant pipeline—and what evidence could change the picture?
Traceable citations · Unknowns marked
About this indication
Prostatic Neoplasms, Castration-Resistant context
Also known as: Androgen-Independent Prostatic Neoplasm, Androgen-Insensitive Prostatic Neoplasm, Androgen-Resistant Prostatic Neoplasm, Castration-Resistant Prostatic Neoplasm, Neoplasms, Androgen-Independent Prostatic, Neoplasms, Androgen-Insensitive Prostatic, Neoplasms, Androgen-Resistant Prostatic, Prostatic Neoplasms, Hormone Refractory
Narrower concepts tracked separately: Castration-Resistant Prostatic Cancer
Prevalence
256.0 / 100K
Incidence
111.0 / 100K/yr
Frequently asked questions
How many clinical trials target Prostatic Neoplasms, Castration-Resistant?
There are 14 clinical trials targeting Prostatic Neoplasms, Castration-Resistant tracked by BioSniper.
What is the prevalence of Prostatic Neoplasms, Castration-Resistant?
The estimated prevalence of Prostatic Neoplasms, Castration-Resistant is approximately 256.0 per 100,000 population.